Heparinkezelés hatása a melanoma áttétké pzésére preklinikai modellben

J. Tóvári, Bereczky Bíborka, Gilly Réka, Skopál Judit, Vágó Ágnes, J. Tímár

Research output: Contribution to journalArticle

Abstract

Heparin treatment, at human equivalent doses, modulates coagulation parameters in mice similarly to the human situation. Heparins were tested in various melanoma metastasis models for their antimetastatic acitvity. Heparins were active against melanoma metastasis without influencing the primary tumor. Tumor cell-induced platelet aggregation was not the primary target of heparins, since melanoma cells were not active in this respect. Our results support the notion that heparins have antimetastatic acitivity.

Original languageHungarian
Pages (from-to)235-241
Number of pages7
JournalMagyar Onkologia
Volume48
Issue number3
Publication statusPublished - 2004

ASJC Scopus subject areas

  • Oncology

Cite this

Heparinkezelés hatása a melanoma áttétké pzésére preklinikai modellben. / Tóvári, J.; Bíborka, Bereczky; Réka, Gilly; Judit, Skopál; Ágnes, Vágó; Tímár, J.

In: Magyar Onkologia, Vol. 48, No. 3, 2004, p. 235-241.

Research output: Contribution to journalArticle

Tóvári, J, Bíborka, B, Réka, G, Judit, S, Ágnes, V & Tímár, J 2004, 'Heparinkezelés hatása a melanoma áttétké pzésére preklinikai modellben', Magyar Onkologia, vol. 48, no. 3, pp. 235-241.
Tóvári, J. ; Bíborka, Bereczky ; Réka, Gilly ; Judit, Skopál ; Ágnes, Vágó ; Tímár, J. / Heparinkezelés hatása a melanoma áttétké pzésére preklinikai modellben. In: Magyar Onkologia. 2004 ; Vol. 48, No. 3. pp. 235-241.
@article{ed2717873cf847bd928970839a175289,
title = "Heparinkezel{\'e}s hat{\'a}sa a melanoma {\'a}tt{\'e}tk{\'e} pz{\'e}s{\'e}re preklinikai modellben",
abstract = "Heparin treatment, at human equivalent doses, modulates coagulation parameters in mice similarly to the human situation. Heparins were tested in various melanoma metastasis models for their antimetastatic acitvity. Heparins were active against melanoma metastasis without influencing the primary tumor. Tumor cell-induced platelet aggregation was not the primary target of heparins, since melanoma cells were not active in this respect. Our results support the notion that heparins have antimetastatic acitivity.",
author = "J. T{\'o}v{\'a}ri and Bereczky B{\'i}borka and Gilly R{\'e}ka and Skop{\'a}l Judit and V{\'a}g{\'o} {\'A}gnes and J. T{\'i}m{\'a}r",
year = "2004",
language = "Hungarian",
volume = "48",
pages = "235--241",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Heparinkezelés hatása a melanoma áttétké pzésére preklinikai modellben

AU - Tóvári, J.

AU - Bíborka, Bereczky

AU - Réka, Gilly

AU - Judit, Skopál

AU - Ágnes, Vágó

AU - Tímár, J.

PY - 2004

Y1 - 2004

N2 - Heparin treatment, at human equivalent doses, modulates coagulation parameters in mice similarly to the human situation. Heparins were tested in various melanoma metastasis models for their antimetastatic acitvity. Heparins were active against melanoma metastasis without influencing the primary tumor. Tumor cell-induced platelet aggregation was not the primary target of heparins, since melanoma cells were not active in this respect. Our results support the notion that heparins have antimetastatic acitivity.

AB - Heparin treatment, at human equivalent doses, modulates coagulation parameters in mice similarly to the human situation. Heparins were tested in various melanoma metastasis models for their antimetastatic acitvity. Heparins were active against melanoma metastasis without influencing the primary tumor. Tumor cell-induced platelet aggregation was not the primary target of heparins, since melanoma cells were not active in this respect. Our results support the notion that heparins have antimetastatic acitivity.

UR - http://www.scopus.com/inward/record.url?scp=84874988456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874988456&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 235

EP - 241

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -